semaglutide from india Novo Nordisk cuts Wegovy price by up to 37% in Zydus, Lupin to Co-Market Generic
Description
Several drugmakers are looking to grab a slice of the potential $150 billion weight-loss drug market, aiming to challenge the dominance of Novo Nordisk's #Wegovy(#semaglutide)& Eli Lilly and Company's #Zepbound(#tirzepatide)
Eli Lilly CEO David Ricks announces details of the Medicare GLP-1 bridge program, offering weight loss medications like Fondeo and Zepbound for $50 per month to 20 million eligible Medicare Part D patients starting July 1.
Prescription requirements and eligibility must be confirmed during medical consultation
Meet your protein needs while on GLP-1 RAs.
